Baselga J et al. Phase II study of efficacy, safety, and pharmacokinetics of trastuzumab monotherapy administered on a 3-weekly schedule. J Clin Oncol 2005;23(10):2162-71. Abstract

Chan A et al. Long term survival of vinorelbine (N) and trastuzumab (H) as first line therapy for HER2-positive metastatic breast cancer patients (HER2+MBC) (pts). Proc ASCO 2005;Abstract 587.

Extra J et al. Long-term survival demonstrated with trastuzumab plus docetaxel: 24-month data from a randomised trial (M77001) in HER2-positive metastatic breast cancer. Proc ASCO 2005;Abstract 555.

Gralow JR. Optimizing the treatment of metastatic breast cancer. Breast Cancer Res Treat 2005;89(Suppl 1):9-15. Abstract

Khan SA et al. Does aggressive local therapy improve survival in metastatic breast cancer? Surgery 2002;132(4):620-6. Abstract

Leyland-Jones B. A novel loading regimen for trastuzumab in MBC: Boost serum levels in early cycles. Poster. ASCO 2005. No abstract available

Leyland-Jones B et al. Pharmacokinetics, safety, and efficacy of trastuzumab administered every three weeks in combination with paclitaxel. J Clin Oncol 2003;21(21):3965-71. Abstract

Marcom PK et al. A phase II trial of letrozole and trastuzumab for ER and/or PgR and HER2 positive metastatic breast cancer: Final results. Proc ASCO 2005;Abstract 596.

Marty M et al. Anthracyclines vs taxanes plus trastuzumab in HER2-positive metastatic breast cancer (MBC): A cross trial comparison of pivotal studies. Proc ASCO 2005;Abstract 743.

Montemurro F et al. Outcome of patients with HER2+ advanced breast cancer (ABC) progressing during trastuzumab (T)-based treatment. Proc ASCO 2005;Abstract 593.

Slamon DJ et al. Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2. N Engl J Med 2001;344(11):783-92. Abstract

Tripathy D et al. Safety of treatment of metastatic breast cancer with trastuzumab beyond disease progression. J Clin Oncol 2004;22(6):1063-70. Abstract